Research progress of BRD4 in head and neck squamous cell carcinoma: Therapeutic application of novel strategies and mechanisms
J Tang, H Chen, H Fan, T Chen, C Pu, Y Guo - Bioorganic & Medicinal …, 2024 - Elsevier
Abstract Bromodomain-containing protein 4 (BRD4) belongs to the bromodomain and extra-
terminal domain (BET) protein family, which plays a crucial role in recognizing acetylated …
terminal domain (BET) protein family, which plays a crucial role in recognizing acetylated …
[HTML][HTML] Proteolysis Targeting Chimera Agents (PROTACs): New Hope for Overcoming the Resistance Mechanisms in Oncogene-Addicted Non-Small Cell Lung …
N Cordani, D Nova, L Sala, MI Abbate… - International Journal of …, 2024 - mdpi.com
Non-small cell lung cancer (NSCLC) remains a disease with a poor prognosis despite the
advances in therapies. NSCLC with actionable oncogenic alterations represent a subgroup …
advances in therapies. NSCLC with actionable oncogenic alterations represent a subgroup …
PROTACs in platelets: emerging antithrombotic strategies and future perspectives
JS Trory, J Vautrinot, CJ May, I Hers - Current Opinion in …, 2025 - journals.lww.com
Platelets are susceptible to targeted protein degradation by CRBN ligand-based PROTACs
and have limited ability to resynthesise proteins, ensuring long-term downregulation of …
and have limited ability to resynthesise proteins, ensuring long-term downregulation of …
Identification of E3 ubiquitin ligase-associated prognostic genes and construction of a prediction model for uterine cervical cancer based on bioinformatics analysis
Z Yan, J Yu, S Wang, W Wen, M Xin, X Li - Discover Oncology, 2024 - Springer
E3 ligases are engaged in a variety of physiological processes within cells and use ubiquitin-
labeled substrates to control their activity and stability. Although some research has …
labeled substrates to control their activity and stability. Although some research has …